Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
Kidney Week 2021: American Society of Nephrology Annual Meeting
November 04 - 07, 2021; Virtual
November 04 - 07, 2021Virtual
KidneyWeek 2021ADVOCATE: Avacopan Shows Renal Benefits in ANCA VasculitisThe oral C5a receptor inhibitor could allow for the 'previously unthinkable' avoidance of steroid treatment, and related adverse effects, in those with ANCA-associated vasculitis.
Medscape Medical News, November 16, 2021
KidneyWeek 2021Advanced CKD Doesn't Derail Empagliflozin in EMPEROR-PreservedA prespecified data analysis from EMPEROR-Preserved in patients with HFpEF showed consistent efficacy and safety results for empagliflozin regardless of chronic kidney disease status.
Medscape Medical News, November 12, 2021
KidneyWeek 2021'Strong Evidence' Oral Steroids Slow IgA Nephropathy ProgressionA 6- to 9-month regimen of oral methylprednisolone showed clear evidence of slowing renal progression of IgA nephropathy, but safety-driven dose adjustment during the study left the findings uncertain.
Novel Drug Slows Progression of Diabetic Kidney DiseaseFinerenone, a selective, nonsteroidal mineralocorticoid receptor antagonist, significantly reduced both renal and cardiovascular
events, with good tolerability, in the FIDELIO-DKD trial.
Medscape Medical News, Oct 23, 2020
Cardiovascular Safety Results for Anemia Drug DisappointVadadustat did not meet the noninferiority criteria for cardiovascular safety in the PRO2TECT studies that compared the HIF
inhibitor with an erythropoiesis-stimulating agent.
Medscape Medical News, Oct 26, 2020
Cardiovascular Safety Results for Anemia Drug DisappointThe benefits of SGLT2 inhibitors are seen in patients with heart failure and in those with chronic kidney disease, data from
two pivotal trials, EMPEROR-Reduced and DAPA-CKD, show.
